No Data
No Data
Beijing Succeeder Technology Inc. (688338.SH): has repurchased 0.4309% of its shares.
Beijing Succeeder Technology Inc. (688338.SH) announced that as of August 31, 2024, the company has repurchased a total of 457,382 shares, accounting for 0.4309% of the total share capital. The highest purchase price was 22.5 yuan/share, the lowest purchase price was 20.65 yuan/share, and the total amount paid was 9,950,854.73 yuan (excluding stamp duty, transaction commissions, and other transaction fees).
Beijing Succeeder Technology Inc. 2024 Half-Year Report
Summary of Succeeder Technology Inc.'s 2024 semi-annual report
Beijing Succeeder Technology Inc. (688338.SH): The net income in the first half of the year was 62.72 million yuan, an increase of 4.15% compared to the same period last year.
On August 21, Succeeder Technology Inc. (688338.SH) released its semi-annual report. In the first half of the year, the company achieved revenue of 0.159 billion yuan, a year-on-year growth of 12.40%. The net income attributable to shareholders of listed companies was 62.72 million yuan, a year-on-year growth of 4.15%. The net income attributable to shareholders of listed companies after deducting non-recurring gains and losses was 62.26 million yuan, a year-on-year growth of 3.63%. In response to changes in the external environment, the company will comprehensively promote the SMART-8800 coagulation pipeline and SF-9200 fully automatic...
Beijing Succeeder Technology Inc. (688338.SH): has repurchased 0.1526% of its shares.
On August 2, Gelon Hui reported that Beijing Succeeder Technology Inc. (688338.SH) has announced that as of July 31, 2024, the company has cumulatively repurchased 161,947 shares, accounting for 0.1526% of the total share capital of the company, with the highest purchase price of 21 yuan/share, the lowest purchase price of 20.65 yuan/share, and a total amount paid of 3,383,234.57 yuan (excluding transaction fees such as stamp duty and trading commission).
Beijing Succeeder Technology Inc. (688338.SH): At present, the healthcare bureau has not yet carried out the national procurement of coagulation.
Recently, during an investor reception, Beijing Succeeder Technology Inc. (688338.SH) stated that centralized procurement is a major trend in the National Medical Insurance Bureau's cost reduction and efficiency enhancement policies. Currently, the Medical Insurance Bureau has not carried out centralized procurement of blood coagulation reagents on a national scale. Currently, the market share of blood coagulation reagents is mainly held by imported brands, and the share of domestic substitutes is expected to increase after centralized procurement. Overall, whether or not blood coagulation reagents are included in centralized procurement, the company will always strive to improve the cost-effectiveness and competitiveness of its products, seize opportunities brought about by industry changes to enhance its customer base and the quantity, and thus increase its market share.
No Data
No Data